Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Options ($5 call Oct-2022 for THTX Nasdaq)

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Sep 28, 2022 1:33pm

129 Views

Post# 34992748

RE:Options ($5 call Oct-2022 for THTX Nasdaq)

I can pull up a page on Bloomberg and see options activity and open interest. I don't see that volume today but I imagine the ZipTrader effect was in play with options on Monday that would have caused a big jump in volume. There is currently 711 call options in place for October at $2.50 and 1,037 call options for October at a strike price of $5.

stephanedodier wrote: Hi,

Is anyone that has more background then me on option trading can validate this statement?

https://twitter.com/runaway_vol/status/1575129966240481282
(Theratechnologies Inc. $TH had an unusually high call volume of 7.5K this is 132.3K% of the 30d avg call volume of 5.7)

thanks